ストックスクリーナーアプリを入手
24.45
5.82%
-1.51
プレマーケット:
24.93
0.48
+1.96%
前日終値:
$25.96
開ける：
$26.1
24時間の取引高:
418.14K
Relative Volume:
1.60
時価総額：
$1.68B
収益：
-
当期純損益:
$-48.26M
株価収益率:
-30.95
EPS:
-0.7899
ネットキャッシュフロー:
$-45.04M
1週間 パフォーマンス:
-14.87%
1か月 パフォーマンス:
-12.99%
6か月 パフォーマンス:
+82.60%
1年 パフォーマンス:
+75.77%
1日の値動き範囲:
$23.43
$26.10
1週間の範囲:
$23.43
$29.15
52週間の値動き範囲:
$12.04
$31.44
Gh Research Plc Stock (GHRS) Company Profile
Compare GHRS vs VRTX, REGN, MRNA, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GHRS
Gh Research Plc
|
24.45 | 1.68B | 0 | -48.26M | -45.04M | -0.7899 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Gh Research Plc Stock (GHRS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-13 | 開始されました | Needham | Buy |
| 2025-06-04 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-03-13 | 開始されました | Guggenheim | Buy |
| 2025-03-07 | 開始されました | RBC Capital Mkts | Outperform |
| 2025-02-13 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-08-16 | 開始されました | H.C. Wainwright | Buy |
| 2022-06-16 | 開始されました | ROTH Capital | Buy |
すべてを表示
Gh Research Plc (GHRS) 最新ニュース
(GHRS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
GH Research gets FDA clearance to start phase 3 trial for new depression treatment in 2026 - Pluang
GH Research: 'Buy' GH001 TRD Advancement Presses On And Expansion Opportunities - Seeking Alpha
GH Research PLC (GHRS): Investor Outlook on a Biotech Stock with a 49% Potential Upside - DirectorsTalk Interviews
GH Research PLC (NASDAQ: GHRS) Files September 2026 Report Under 1934 Exchange Act - kalkinemedia.com
GH Research PLC (GHRS) Stock Price Quote Today & Current Price Chart - Capital.com
GH Research Plans Investor Meetings at Morgan Stanley Global Healthcare Conference - TipRanks
$GHRS Q2 '26 Earnings Results & Recap - Stocktwits
GH Research (GHRS) plans one-on-one talks at 2026 Morgan Stanley healthcare event - Stock Titan
Price-Driven Insight from (GHRS) for Rule-Based Strategy - news.stocktradersdaily.com
GH Research (GHRS) director gets 2,303 options not exercisable until 2028 - Stock Titan
GH Research PLC (GHRS) Dips 1.56% as Shares Sit at Midpoint of Trading RangeSwing Entry Signals - dars.gov.et
GHRS Q2 2026 Earnings: Loss Narrows More Than Expected as Investors Focus on PipelineEarnings Stability Report - dars.gov.et
(GHRS) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
GH Research (GHRS) Slides 2.48% to $27.94 as Shares Approach Key SupportBearish Pattern Stocks - vinanet.vn
Net margin % of GH Research Plc – HAM:1KA - TradingView
Net income before discontinued operations of GH Research Plc – HAM:1KA - TradingView
GH Research Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
How Rising Losses And Milestone Spending At GH Research (GHRS) Have Changed Its Investment Story - simplywall.st
GHRS Q2 2026 Earnings: Narrower Loss of -$0.23 Per Share Beats Estimates by 25.6%Earnings Trend Analysis - vinanet.vn
Zacks Research Upgrades GH Research (NASDAQ:GHRS) to Hold - MarketBeat
GHRS Q2 2026 Earnings: Narrower Loss Beats Estimates as Pipeline Progress Takes Center Stage - dars.gov.et
RA Capital discloses 7.1% GH Research PLC (GHRS) stake in Schedule 13G/A - Stock Titan
Lynx1 Capital Management (NASDAQ: GHRS) reports 19.3% stake in GH Research - Stock Titan
GH Research PLC (NASDAQ:GHRS) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
GH Research PLC Director Duncan Moore Granted 2,202 Share Options - Kalkine Media
GH Research PLC (GHRS) director receives 2,202 fully vested share options - Stock Titan
GH Research PLC (GHRS) director receives 2,202 options at $0.025 strike - Stock Titan
GH Research PLC (GHRS) grants 102,202 share options to director Michael Forer - Stock Titan
GHRS Q2 2026 Earnings: Narrower-than-Expected Loss Delivers 25.6% EPS SurpriseFull Year Guidance - dars.gov.et
GH Research (NASDAQ:GHRS) Sees Strong Trading VolumeShould You Buy? - MarketBeat
FY2026 EPS Estimates for GH Research Boosted by Analyst - MarketBeat
GH Research (GHRS) Retreats 2.4% to $29.53 as Clinical-Stage Biotech ConsolidatesTechnical Analysis - siam.in
Trading the Move, Not the Narrative: (GHRS) Edition - Stock Traders Daily
H.C. Wainwright reiterates GH Research stock rating on FDA progress By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates GH Research stock rating on FDA progress - Investing.com
Is GH Research’s Rising Loss Per Share Reframing the GHRS Cash Burn Narrative? - simplywall.st
GH Research (NASDAQ:GHRS) Posts Quarterly Earnings Results, Beats Expectations By $0.06 EPS - MarketBeat
GH Research (NASDAQ:GHRS) Upgraded at Wall Street Zen - MarketBeat
GH Research stock hits all-time high at 31.41 USD By Investing.com - Investing.com India
GH Research (NASDAQ:GHRS) Reaches New 12-Month High Following Earnings Beat - marketbeat.com
GH Research stock hits all-time high at 31.41 USD - Investing.com
GH Research (NASDAQ:GHRS) Stock Price Expected to Rise, Cantor Fitzgerald Analyst Says - MarketBeat
GH Research PLC (GHRS) Stock Analysis: A Biotech Powerhouse with 30.55% Upside Potential - DirectorsTalk Interviews
GH Research PLC (GHRS) Stock News Today - TradingKey
GH Research PLC (GHRS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
GH Research (GHRS) Dips 1.21% to $30.27 Amid Clinical-Stage Biotech CautionTechnical Analysis Picks - vinanet.vn
GH Research PLC Stock 12‑Month Price Target Raised to $41.1, Implies 41% Upside - TradingView
Needham & Company LLC Raises GH Research (NASDAQ:GHRS) Price Target to $39.00 - MarketBeat
GH Research PLC Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
GHRS: GH001 achieves rapid, sustained TRD remission with fewer visits and robust IP protection - tradingview.com
Gh Research Plc (GHRS) 財務データ
収益
当期純利益
現金流量
EPS
1.11%
1.87%
大文字化:
|
ボリューム (24 時間):